Introduction to the launch time and latest progress of marketing promotion of amivantamab in China

Amivantamab is a bispecific antibody drug developed by Johnson & Johnson. It is mainly used to treat patients with non-small cell lung cancer carrying EGFR exon 20 insertion mutations. 2025In February 2025, evantumumab was officially approved by the China National Medical Products Administration (NMPA) and launched in China. It became the first antibody drug approved for this specific mutation type, filling the treatment gap in this field.

Although evantumumab has been launched in China, due to the short time and market supply has not yet been fully popularized, domestic patients may face certain difficulties in purchasing it directly. At present, the drug has not been included in the national medical insurance list, and patients need to purchase it at their own expense. According to the latest market information, the price of a single dose of evantumumab is approximately RMB 10,000 to RMB 15,000, and the first month’s treatment cost may be approximately RMB 40,000 to RMB 60,000.

In order to reduce the financial burden on patients, some patients will consider purchasing evantumumab through overseas channels, especially the original research version listed in Hong Kong, China, with a relatively transparent price of about 10,000 yuan. At the same time, relevant domestic companies are also developing generic versions of the drug, and it is expected that a more affordable domestic version may be launched in the next few years.

Overall, the launch of evantumumab has brought new treatment hope to Chinese lung cancer patients, especially for patients carrying EGFR exon 20 insertion mutations. With the deepening of market promotion and the gradual improvement of medical insurance policies, patients' access to the drug and economic pressure are expected to be further improved.

Reference: https://go.drugbank.com/drugs/